Epidemiology of Asthma Mortality

  • Richard Beasley
  • Meme Wijesinghe
  • Kyle Perrin
Part of the Allergy Frontiers book series (ALLERGY, volume 1)

In order to interpret data on long-term time trends in asthma mortality, it is necessary to firstly review the key issues of the accuracy of death certification, disease classification and diagnostic fashion. As the diagnosis of asthma as the cause of death is firmly established in the 5–34-year age group [1–6], long-term trends in asthma mortality within countries and comparisons between countries are normally confined to this age group. Although most deaths occur in the older age group, the accuracy of asthma as the cause of death declines with increasing age due to confounding with other respiratory disorders such as chronic obstructive pulmonary disease (COPD) or the presence of intercurrent medical conditions.

Changes in disease classification coding are also relevant, with the International Classification of Diseases (ICD) implementing major revisions in the coding of asthma. The ICD revisions occur about every 10 years, usually involving the manner in which deaths due to asthma and bronchitis are coded. These revisions usually have minimal effect on the coding in the 5–34-year age group [7–11].


Fluticasone Propionate Allergy Clin Immunol Case Fatality Rate Inhale Corticosteroid Therapy Asthma Mortality 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    British Thoracic Association, BTA Research Committee (1984) Accuracy of death certificates in bronchial asthma. Thorax 39:505–509.Google Scholar
  2. 2.
    Sears MR, Rea HH, de Boer G, Beaglehole R, Gillies AJ, Holst PE, O'Donnell T V, Rothwell RP (1986) Accuracy of certification of deaths due to asthma: a national study. Am J Epidemol 124:1004–1011.Google Scholar
  3. 3.
    Sidenius KE, Munch EP, Madsen F, Lange P, Viskum K, Soes-Petersen U (2000) Accuracy of recorded asthma deaths in Denmark in a 12-months period in 1994/95. Respir Med 94:373–377.PubMedCrossRefGoogle Scholar
  4. 4.
    Sirken MG, Rosenberg HM, Chevarley FM, Curtin LR (1987) The quality of cause-of-death statistics. Am J Pub Health 77:137–139.CrossRefGoogle Scholar
  5. 5.
    Jenkins M, Rubinfeld A, Robertson C, Bowes G (1992) Accuracy of asthma death statistics in Australia. Aust J Public Health 16:427–429.PubMedGoogle Scholar
  6. 6.
    Hunt LW, Silverstein MD, Reed CE, O'Connell EJ, O'Fallon WM, Yunginger JW (1993) Accuracy of the death certificate in a population-bases study of asthmatic patients. JAMA 259:1947–1952.CrossRefGoogle Scholar
  7. 7.
    Beasley R, Smith K, Pearce N, Crane J, Burgess C, Culling C (1990) Trends in asthma mortality in New Zealand, 1908–1986. Med J Aust 152:570–573.PubMedGoogle Scholar
  8. 8.
    Jackson R (1993) A century of asthma mortality. In: Beasley R, Pearce NE (eds) The role of beat agonist therapy in asthma mortality.CRC Press, New York, pp 29–47.Google Scholar
  9. 9.
    Jackson R, Sears MR, Beaglehole R, Rea HH (1988) International trends in asthma mortality: 1970 to 1985. Chest 94:914–918.PubMedCrossRefGoogle Scholar
  10. 10.
    Dobbin CJ, Miller J, van der Hoek R, Baker DF, Cumming R, Marks GB (2004) The effects of age, death period and birth cohort on asthma mortality rates in Australia. Int J Tuberc Lung Dis 8:1429–1436.PubMedGoogle Scholar
  11. 11.
    Weiss KB, Gergen PJ, Wagener DK (1993) Breathing better or wheezing worse? The changing epidemiology of asthma morbidity and mortality. Ann Rev Publ Health 14:491–513.Google Scholar
  12. 12.
    Speizer FE, Doll R (1968) A century of asthma deaths in young people. Br Med J 3:245–246.PubMedGoogle Scholar
  13. 13.
    Burney PGJ (1989) The effect of death certification practice on recorded national asthma mortality rates. Revue d'Epidemiologie et de Sante Publique 37:385–389.PubMedGoogle Scholar
  14. 14.
    Kelson MC, Heller RF (1983) The effect of death certification and coding practices on observed differences in respiratory disease mortality in 8 EEC. countries. Revue d'Epidemiologie et de Sante Publique 31:423–432.PubMedGoogle Scholar
  15. 15.
    Osler W (1901) The principles and practice of medicine, 4th edn. Pentland, Edinburgh.Google Scholar
  16. 16.
    Beasley CRW, Pearce NE, Crane J (2000) Epidemiology of asthma mortality. In: Giembycz MA, O'Connor BJ (eds) Asthma: epidemiology, anti-inflammatory therapy and future trends. Birkhauser Verlag, Basel, pp 1–24.Google Scholar
  17. 17.
    Speizer FE, Doll R, Heaf P (1968) Observations on recent increase in mortality from asthma. Br Med J 1:335–339.PubMedGoogle Scholar
  18. 18.
    Stolley PD (1972) Why the United States was spared an epidemic of deaths due to asthma. Am Rev Respir Dis 105:883–890.PubMedGoogle Scholar
  19. 19.
    Inman WHW, Adelstein AM (1969) Rise and fall of asthma mortality in England and Wales in relation to use of pressurized aerosols. Lancet ii:279–285.CrossRefGoogle Scholar
  20. 20.
    Speizer FE, Doll R, Heaf P, Strang LB (1968) Investigation into use of drugs preceding death from asthma. Br Med J 1:339–343.PubMedGoogle Scholar
  21. 21.
    Fraser PM, Speizer FE, Waters SD, Doll R, Mann NM (1971) The circumstances preceding death from asthma in young people in 1968 to 1969. Br J Dis Chest 652:71–84.Google Scholar
  22. 22.
    Collins JM, McDevitt DG, Shanks RG, Swanton JG (1969) The cardio-toxicity of isoprenaline during hypoxia. Br J Pharmacol 36:35–45.PubMedGoogle Scholar
  23. 23.
    Lockett MF (1965) Dangerous effects of isoprenaline in myocardial failure. Lancet ii:104–106.CrossRefGoogle Scholar
  24. 24.
    Lowell FC, Curry JJ, Schiller IW (1949) A clinical and experimental study of isoprel in spontaneous and induced asthma. N Engl J Med 240:45–51.CrossRefGoogle Scholar
  25. 25.
    Keighley JF (1966) Iatrogenic asthma associated with adrenergic aerosols. Ann Int Med 65:985–995.PubMedGoogle Scholar
  26. 26.
    van Metre TE (1969) Adverse effects of inhalation of excessive amounts of nebulised isoproterenol in status asthmaticus. J Allergy 43:101–113.PubMedCrossRefGoogle Scholar
  27. 27.
    Stolley PD, Schinnar R (1978) Association between asthma mortality and isoproterenol aerosols: a review. Prev Med 7:319–338.CrossRefGoogle Scholar
  28. 28.
    Mitsui S (1986) Death from bronchial asthma in Japan. Sino-Jpn. J Allergol Immunol 3:249–257.Google Scholar
  29. 29.
    Venning GR (1983) Identification of adverse reactions to new drugs. 1. What have been the important adverse reactions since thalidomide? Br Med J 286:199–202.CrossRefGoogle Scholar
  30. 30.
    Pearce N, Hensley MJ (1998) Epidemiologic studies of beta-agonists and asthma deaths. Epidemiol Rev 20:173–186.PubMedGoogle Scholar
  31. 31.
    Jackson RT, Beaglehole R, Rea HH, Sutherland DC (1982) Mortality from asthma: a new epidemic in New Zealand. Br Med J 285:771–774.Google Scholar
  32. 32.
    Crane J, Burgess C, Pearce N, Beasley R (1993) The β-agonist controversy: a perspective. Eur Respir Rev 3:475–482.Google Scholar
  33. 33.
    Mugge A, Posselt D, Reimer U, Schmitz W, Scholz H (1985) Effects of beta 2-adrenceptor agonist, fenoterol and salbutamol, on force of contraction in isolated human ventricular myocardium. Klin Wochenschr 63:26–31.PubMedCrossRefGoogle Scholar
  34. 34.
    Wagner J, Reinhardt, Schumann HJ (1973) Comparison of the bronchodilator and cardiovascular actions of isoprenaline, Th 1165a, tertutaline and salbutamol in cats and isolated organ preparations. Res Exp Med 162:49–62.CrossRefGoogle Scholar
  35. 35.
    Bremner P, Siebers R, Crane J, Beasley R, Burgess C (1996) Partial vs full β-receptor agonism: A clinical study of inhaled albuterol and fenoterol. Chest 109:957–962.PubMedCrossRefGoogle Scholar
  36. 36.
    Crane J, Pearce N, Flatt A, Burgess C, Jackson R, Kwong T, Ball M, Beasley R (1989) Prescribed fenoterol and death from asthma in New Zealand, 1981–83: A case control study. Lancet 1:917–922.PubMedCrossRefGoogle Scholar
  37. 37.
    Pearce N, Grainger J, Atkinson M, Crane J, Burgess C, Culling C, Windom H, Beasley R (1990) Case—control study of prescribed fenoterol and death from asthma in New Zealand 1977–1981. Thorax 45:170–175.PubMedGoogle Scholar
  38. 38.
    Grainger J, Woodman K, Pearce N, Crane J, Burgess C, Keane A, Beasley R (1991) Prescribed fenoterol and death from asthma in New Zealand, 1981–1987: A further case—control study. Thorax 46:105–111.PubMedGoogle Scholar
  39. 39.
    Beasley R, Burgess C, Pearce N, Woodman K, Crane J (1994) Confounding by severity does not explain the association between fenoterol and asthma death. Clin Exp Allergy 24:660–668.PubMedCrossRefGoogle Scholar
  40. 40.
    Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, Cockcroft D, Boivin JF, McNutt M, Buist AS, Rebuck AS (1992) The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 326:501–506.PubMedGoogle Scholar
  41. 41.
    Suissa S, Ernst P, Boivin J-F, Horwitz RI, Habbick B, Cockroft D, Blais L, McNutt M, Buist AS, Spitzer WO (1994) A cohort analysis of excess mortality in asthma and the use of inhaled β-agonists. Am J Respir Crit Care Med 149:604–610.PubMedGoogle Scholar
  42. 42.
    Matsui T (1996) Asthma deaths and β2-agonists. Current advances in paediatric allergy and clinical epidemiology. In: K Shimomiya (ed). Selected proceedings from the 32nd annual meeting of the Japanese Society of Paediatric Allergy and Clinical Immunology. Churchill Livingstone, Tokyo, pp 161–164.Google Scholar
  43. 43.
    Beasley R, Nishima S, Pearce N, Crane J (1998) β-agonists therapy and asthma mortality in Japan. Lancet 351: 1406–1407.PubMedCrossRefGoogle Scholar
  44. 44.
    Criée C-P, Quast CH, Ludtke R, Laier-Groeneveld G, Huttemann U (1993) Use of beta agonists and mortality in patients with stable COPD. Eur Respir J 6:426S (abstract).Google Scholar
  45. 45.
    van der Merwe L, de Klerk A, Kidd M, Bardin PG, van Schalkwyk EM (2006) Case—control study of severe life threatening asthma (SLTA) in a developing community. Thorax 61:756–760.PubMedCrossRefGoogle Scholar
  46. 46.
    Pearce N, Beasley R, Crane J, Burgess C, Jackson R (1995) End of the New Zealand mortality epidemic. Lancet 345:41–44.PubMedCrossRefGoogle Scholar
  47. 47.
    Sears MR (1991) Worldwide trends in asthma mortality. Bull Int Union Tuberc Lung Dis 66:79–83.PubMedGoogle Scholar
  48. 48.
    Pearce NE, Crane J (1993) Epidemiological methods for studying the role of beta receptor agonist therapy in asthma mortality. In: Beasley R, Pearce NE (eds). The role of beta receptor agonist therapy in asthma mortality. CRC Press, New York, pp 68–83.Google Scholar
  49. 49.
    Barrett TE, Strom BL (1995) Inhaled beta-adrenergic receptor agonists in asthma: more harm than good? Am J Respir Crit Care Med 151:574–577.PubMedGoogle Scholar
  50. 50.
    Gibson P, Henry D, Francis L, Cruickshank D, Dupen F, Higginbotham N, Henry R, Sutherland D (1993) Association between availability of non-prescription beta 2-agonist inhalers and undertreatment of asthma. Br Med J 306:1514–1518.Google Scholar
  51. 51.
    Pearce N, Crane J, Beasley R (1997) Isoprenaline, fenoterol and asthma deaths in Japan. Jpn Soc Pediatr Allergy Clin Immunol 11:307–316.Google Scholar
  52. 52.
    Beasley R, Crane J, Lai CKW, Pearce N (2000) Prevalence and etiology of asthma. J Allergy Clin Immunol 105:S466–S472.PubMedCrossRefGoogle Scholar
  53. 53.
    Kaur B, Butland B (1997) Asthma mortality is falling in most age groups in Scotland. BMJ 315:1014.PubMedGoogle Scholar
  54. 54.
    Wever-Hess J, Wever AMJ (1997) Asthma statistics in the Netherlands 1980–94. Respir Med 91:417–422.PubMedCrossRefGoogle Scholar
  55. 55.
    Baluga JC, Sueta A, Ceni M (2001) Asthma mortality in Uruguay, 1984–1998. Ann Allergy Asthma Immunol 87:124–128.PubMedCrossRefGoogle Scholar
  56. 56.
    Neffen H, Baena-Cagnani C, Passalacqua G, Canonica GW, Rocco D (2006) Asthma mortality, inhaled steroids, and changing asthma therapy in Argentina (1990–1999). Resp Med 100:1431–1435.CrossRefGoogle Scholar
  57. 57.
    Anderson HR, Gupta R, Strachan DP, Limb ES (2007) 50 years of asthma: UK trends from 1955 to 2004. Thorax 62:85–90PubMedCrossRefGoogle Scholar
  58. 58.
    Zar HJ, Stickells D, Toerien A, Wilson D, Klein M, Bateman ED (2001) Changes in fatal and near-fatal asthma in an urban area of South Africa from 1980–1997. Eur Respir J 18:33–37.PubMedCrossRefGoogle Scholar
  59. 59.
    Goldman M, Rachmiel M, Gendler L, Kats Y (2000) Decrease in asthma mortality rate in Israel from 1991–1995: is it related to increased use of inhaled corticosteroids? J Allergy Clin Immunol 105:71–74.PubMedCrossRefGoogle Scholar
  60. 60.
    Lim DL, Ma S, Wang XS, Cutter J, Chew SK (2006) Trends in sales of inhaled corticosteroids and asthma outcomes in Singapore. Thorax 61:362–365.PubMedCrossRefGoogle Scholar
  61. 61.
    Fabre Ortiz DE, Cabrera Perez JF, Armas Perez L, Gonzales Ochoa E (1997) Asthma mortality in Cuba during 1972–1993. Allergol Immunopathol 25:289–292.Google Scholar
  62. 62.
    Markov A (1995) The problem of asthma in the Ukraine. Allergy Proc 16: 269–273.PubMedCrossRefGoogle Scholar
  63. 63.
    Oganov RG, Maslennikova GYa (1999) Asthma mortality in Russia between 1980 and 1989. Eur Respir J 13:287–289.PubMedCrossRefGoogle Scholar
  64. 64.
    CDC Compressed mortality data: underlying causes of death. http://wonder.cdc.gov/mort-SQL.htm. Accessed June 2007.
  65. 65.
    Suissa S. Ernst P, Benayoun S, Maltzan M, Cai B (2000) Low-dose inhaled corticosteroids and the prevention of death from asthma. New Engl J Med 343:332–336.PubMedCrossRefGoogle Scholar
  66. 66.
    Sin DD, Tu JV (2001) Inhaled corticosteroid therapy reduces the risk of rehospitalisation and all-cause mortality in elderly asthmatics. Eur Respir J 17:380–385.PubMedCrossRefGoogle Scholar
  67. 67.
    Lanes SF, Garcia Rodriguez LA, Huerta C (2002) Respiratory medications and risk of asthma death. Thorax 57:683–686.PubMedCrossRefGoogle Scholar
  68. 68.
    Eisner MD, Lieu TA, Chi F, Capra AM, Mendoza GR, Selby JV, Blanc PD (2001) Beta agonists, inhaled steroids, and the risk of intensive care unit admission for asthma. Eur Respir J; 17:233–240.PubMedCrossRefGoogle Scholar
  69. 69.
    Ernst P, Spitzer WO, Suissa S, Cockcroft D, Habbick B, Horwitz RI, Boivin J-F, McNutt M, Buist AS (1992) Risk of fatal and near-fatal asthma in relation to inhaled corticosteroid use. JAMA 268:3462–3464.PubMedCrossRefGoogle Scholar
  70. 70.
    Holt S, Suder A, Weatherall M, Cheng S, Beasley R (2001) Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. BMJ 323:253–256.PubMedCrossRefGoogle Scholar
  71. 71.
    Masoli M, Holt S, Weatherall M, Shirtcliffe P, Beasley R (2006) Inhaled corticosteroid therapy in the management of asthma in adults. In: Li JT (ed) The pharmacotherapy of asthma, vol 212. Taylor & Francis Group, New York, pp 83–115.Google Scholar
  72. 72.
    Gupta R, Anderson HR, Strachan DP, Maier W, Watson L (2005) International trends in admissions and drug sales for asthma. Int J Tuberc Lung Dis 12:138–145.Google Scholar
  73. 73.
    Haahtela T, Klaukka T, Koskela K, Erhola M, Laitinen LA on behalf of the Working Group of the Asthma Programme in Finland 1994–2004 (2001) Asthma programme in Finland: a community problem needs community solutions. Thorax 56:806–814.PubMedCrossRefGoogle Scholar
  74. 74.
    Kumana CR, Kou M, Lauder IJ, Ip MSM, Lam WK (2001) Increasing use of inhaled steroids associated with declining asthma mortality. J Asthma 38:161–167.PubMedCrossRefGoogle Scholar
  75. 75.
    Melissinos CG, Gourgoulianis K, Adamidis SC (1995) Inhaled drug consumption and asthma mortality in Greece. Chest 107:1771–1772.PubMedCrossRefGoogle Scholar
  76. 76.
    AIHW Australian Centre for Asthma Monitoring (2005) Asthma in Australia. AIHW Asthma Series 2. AIHW cat. no. ACM 6. AIHW, Canberra.Google Scholar
  77. 77.
    Masoli M, Fabian D, Holt S, Beasley R (2004) Global burden of asthma. Global Initiative for Asthma (GINA). www.ginasthma.com. Accessed June 2007
  78. 78.
    Burney PGJ, Luczynska C, Chinn S, Jarvis D (1994) The European Community Respiratory Health Survey. Eur Respir J 7:954–960.PubMedGoogle Scholar
  79. 79.
    Asher MI, Keil U, Anderson HR, Beasley R, Crane J, Martinez F, Mitchell EA, Pearce N, Sibbald B, Stewart AW, Strachan D, Weiland SK, Williams HC (1995) International study of asthma and allergies in childhood (ISAAC): rationale and methods. Eur Respir J 8:483–491.PubMedCrossRefGoogle Scholar
  80. 80.
    Ait-Khaled N, Auregan G, Camara LM, Dagli E, Djankine K, Keita B, Ky C, Mahl S, Ngoran K, Pham DL, Sow O, Yousser M, Zidouni N, Enarson DA (2000) Affordability of inhaled corticosteroids as a potential barrier to treatment of asthma in some developing countries. Int J Tuberc Lung Dis 4:268–271.PubMedGoogle Scholar
  81. 81.
    Watson JP, Lewis RA (1997) Is asthma treatment affordable in developing countries. Thorax 52:605–607.PubMedCrossRefGoogle Scholar
  82. 82.
    Weiss KB, Wagener DK (1990) Changing patterns of asthma mortality: identifying populations at high risk. JAMA 264:1683–1687.PubMedCrossRefGoogle Scholar
  83. 83.
    Marder D, Targonski P, Orris P, Persky V, Addington W (1992) Effect of racial and socioeconomic factors on asthma mortality in Chicago. Chest 101(6 Suppl):426S–429S.PubMedCrossRefGoogle Scholar
  84. 84.
    Gupta RS, Carrion-Carire V, Weiss KB (2006) The widening black/white gap in asthma hospitalizations and mortality. J Allergy Clin Immunol 117:351–358.PubMedCrossRefGoogle Scholar
  85. 85.
    Ng TP, Tan WC (1999) Temporal trends and ethnic variations in asthma mortality in Singapore, 1976–1995. Thorax 54:990–994.PubMedGoogle Scholar
  86. 86.
    Anto JM, Sunyer J (1986) Asthma Collaborative Group of Barcelona. A point source asthma outbreak. Lancet i:900–903.CrossRefGoogle Scholar
  87. 87.
    Kwon HJ, Cho SH, Chun Y, Lagarde F, Pershagen G (2002) Effects of the Asian dust events on daily mortality in Seoul, Korea. Environ Res 90:1–5.PubMedCrossRefGoogle Scholar
  88. 88.
    Vijayan VK, Kuppurao KV (1993) Early clinical, pulmonary function and blood gas studies in victims of Bhopal tragedy. Biomed 13:36–42.Google Scholar
  89. 89.
    Misra NP, Pathak R, Gaur KJBS et al. (1987) Clinical profile of gas leak victims in acute phase after Bhopal episode. Ind J Med Res 86(Suppl):11–19.Google Scholar
  90. 90.
    Salinas M, Vega J (1995) The effect of outdoor air pollution on mortality risk: an ecological study from Santiago, Chile. World Health Statist Quart 48:118–125.Google Scholar
  91. 91.
    Lang DM (1998) Atmospheric pollution contributing to fatal asthma. In: Sheffer AL (ed). Fatal asthma. Marcel Dekker, New York, pp 211–236.Google Scholar
  92. 92.
    Campbell MJ, Cogman GR, Holgate ST, Johnston SL (1997) Age specific trends in asthma mortality in England and Wales, 1983–95: results of an observational study. BMJ 314:1439–1441.PubMedGoogle Scholar
  93. 93.
    Cadet B, Robine JM, Leibovici D (1994) Dynamic of asthma mortality in France: seasonal variation and peaking of mortality in 1985–87. Revue d ”Epidemiologique et de Sante Publique 42:103–118.Google Scholar
  94. 94.
    Kimbell-Dunn M, Pearce N, Beasley R (2000) Seasonal variation in asthma hospitalizations and death rates in New Zealand. Respirol 5:241–246.CrossRefGoogle Scholar
  95. 95.
    Weiss KB (1990) Seasonal trends in US asthma hospitalizations and mortality. JAMA 263:2323–2328.PubMedCrossRefGoogle Scholar
  96. 96.
    O'Hallaren MT (1998) Seasonal variations in asthma mortality. In: Sheffer AL (ed). Fatal asthma. Marcel Dekker, New York, pp 397–410.Google Scholar
  97. 97.
    Ito Y, Tamakoshi A, Wakai K, Takagi K, Yamaki K, Ohno Y (2002) Trends in asthma mortality in Japan. J Asthma 39:633–639.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2009

Authors and Affiliations

  • Richard Beasley
    • 1
  • Meme Wijesinghe
    • 1
  • Kyle Perrin
    • 1
  1. 1.Medical Research Institute of New ZealandWellingtonNew Zealand

Personalised recommendations